MacroGenics Margenza rights sale a positive, says Leerink
The Fly

MacroGenics Margenza rights sale a positive, says Leerink

Leerink keeps an Outperform rating on MacroGenics (MGNX) with an $8 price target following the Q3 report. The company recently announced it had sold global rights of Margenza to TerSera Therapeutics for $40M upfront and up to $35M in aggregate sales milestones, the analyst tells investors in a research note. The firm views the deal positively, saying it provides non-dilutive financing and will allow MacroGenics to focus on its pipeline efforts.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App